✦ LIBER ✦

PPAR: a therapeutic target in Parkinson’s disease

✍ Scribed by Rajnish K. Chaturvedi; M. Flint Beal

Book ID: 111180873
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 408 KB
Volume: 106
Category: Article
ISSN: 0022-3042
DOI: 10.1111/j.1471-4159.2008.05388.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

LRRK2 as a therapeutic target in Parkins

LRRK2 as a therapeutic target in Parkinson’s disease

✍ E. K. Tan; A. H. Schapira 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

Milestones in Parkinson's disease therap

Milestones in Parkinson's disease therapeutics

✍ Olivier Rascol; Andres Lozano; Matthew Stern; Werner Poewe 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 228 KB

## Abstract In the mid‐1980s, the treatment of Parkinson's disease was quite exclusively centered on dopatherapy and was focusing on dopamine systems and motor symptoms. A few dopamine agonists and a monoamine oxidase B inhibitor (selegiline) were used as adjuncts in advanced Parkinson's disease. I

Cell Therapeutics in Parkinson’s Disease

✍ Olle Lindvall; Anders Björklund 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 444 KB

Peroxisome proliferator-activated recept

Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease

✍ Broeders, Nilufer; Abramowicz, Daniel 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 540 KB

Novel therapeutic strategies in Parkinso

Novel therapeutic strategies in Parkinson’s disease

✍ Peter Klivenyi; Laszlo Vecsei 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 137 KB

Kynurenines in Parkinson’s disease: ther

Kynurenines in Parkinson’s disease: therapeutic perspectives

✍ Dénes Zádori; Péter Klivényi; József Toldi; Ferenc Fülöp; László Vécsei 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 245 KB